COPENHAGEN (Reuters) - Danish pharmaceutical company H. Lundbeck (LUN.CO) is to buy Chelsea Therapeutics CHTP.O for up to $658 million in a deal that would give it the rights to the U.S. firm’s neurology drug Northera.
Chelsea stockholders will be offered $6.44 per share in cash and contingent value rights (CVRs) that may pay up to $1.50 per share, the two firms said. The total would represent a premium of 59 percent over Wednesday’s closing price of Chelsea shares.
By acquiring Chelsea Therapeutics, Lundbeck would gain the rights to Northera, which was recently approved by the U.S. Food and Drug Administration and is expected to be launched in the third quarter of 2014.
The drug treats a rare form of low blood pressure associated with neurological disorders such as Parkinson’s disease.
Northera has the potential to become the most valuable of Lundbeck’s four neurological drugs in the United States, the Danish company said.
Lundbeck Chief Executive Ulf Wiinberg said at a conference call that the drug “fits perfectly” into Lundbeck’s existing portfolio of drugs, which mainly consists of drugs for brain diseases.
The Chelsea board unanimously approved the transaction but it still requires the approval of Chelsea shareholders which Lundbeck said it expected to receive in the summer.
“Lundbeck is doing this to increase its long-term earnings,” Sydbank analyst Soren Lontoft Hansen told Reuters. “The criteria for success is whether they can generate a peak (annual) sale for Northera of $400 million.”
Shares in Lundbeck were up 0.4 percent at 1325 GMT, outperforming the Danish benchmark index .OMXC20CAP which was down 0.1 percent. Shares in Chelsea Therapeutics were up 32.8 percent in premarket trading.
(This story has been corrected to say that Northera drug could become Lundbeck’s most valuable neurological drug in the United States, not the most valuable drug in Lundbeck’s pipeline)
Editing by Pravin Char